Amyotrophic Lateral Sclerosis
Published May 31, 2001
N Engl J Med 2001;344:1688-1700
DOI: 10.1056/NEJM200105313442207
Abstract
Charcot described amyotrophic lateral sclerosis (ALS) in 1874. Despite progress, this creeping paralysis, known colloquially as Lou Gehrig's disease, is still not visibly affected by available therapies. However, advances in genetics have accelerated the pace of ALS research in the past decade, promising more effective treatment.
Definition of the Disease
ALS has two meanings. In one sense, it refers to several adult-onset conditions characterized by progressive degeneration of motor neurons (Figure 1). In the United Kingdom, the term motor neuron disease is used for these disorders. In the second sense, ALS refers to one specific form of motor neuron disease . . .
Notes
Dr. Shneider is the recipient of a Howard Hughes Medical Institute Postdoctoral Research Fellowship for Physicians and a Mentored Clinical Scientist Career Development Award (K08) from the National Institute of Neurological Disease and Stroke.
Information & Authors
Information
Published In
Copyright
Copyright © 2001 Massachusetts Medical Society. All rights reserved.
For personal use only. Any commercial reuse of NEJM Group content requires permission.
History
Published online: May 31, 2001
Published in issue: May 31, 2001
Topics
Authors
Affiliations
From the Eleanor and Lou Gehrig MDA/ALS Center, Neurological Institute, Columbia–Presbyterian Medical Center, New York–Presbyterian Hospital, and Columbia University College of Physicians and Surgeons — all in New York.
Metrics & Citations
Metrics
Altmetrics
Citations
Export citation
Select the format you want to export the citation of this publication.
Cited by
- A case study of comprehensive association analysis and risk prediction of amyotrophic lateral sclerosis in a Chinese population, Molecular Biology Reports, 53, 1, (2026).https://doi.org/10.1007/s11033-026-12221-y
- Genetic contributions to mitochondrial dysfunction in amyotrophic lateral sclerosis etiology, Human Genetics and Genomics Advances, 7, 3, (100614), (2026).https://doi.org/10.1016/j.xhgg.2026.100614
- Isoform-specific steric zippers drive aberrant assembly and mislocalization of shortened TDP-43, Science Advances, 12, 26, (2026).https://doi.org/10.1126/sciadv.ady0256
- Targeting mtDNA to Modulate Mitochondrial Dysfunction in Neurodegenerative Diseases, Molecular Neurobiology, 63, 1, (2026).https://doi.org/10.1007/s12035-026-06008-2
- Data-driven subtyping and staging of ALS: A multicenter, longitudinal, deformation-based morphometry study, Imaging Neuroscience, 4, (2026).https://doi.org/10.1162/IMAG.a.1264
- Artificial intelligence and enabled technologies for neurological disorders: A narrative review and critical analysis, Intelligent Medicine, 6, 3, (322-335), (2026).https://doi.org/10.1016/j.imed.2025.12.004
- Evaluation of Digital Technologies for Home‐Based Assessment in People With Amyotrophic Lateral Sclerosis, Annals of Clinical and Translational Neurology, (2026).https://doi.org/10.1002/acn3.70429
- Exploring and Targeting the Connection of Iron and Copper Homeostasis to Neurodegenerative Diseases, MedComm, 7, 6, (2026).https://doi.org/10.1002/mco2.70766
- The Bright and Dark Sides of Nitric Oxide in Neurodegenerative Diseases, Journal of Personalized Medicine, 16, 5, (246), (2026).https://doi.org/10.3390/jpm16050246
- BDNF insufficiency exacerbates ALS progression, Cell Reports Medicine, 7, 5, (102758), (2026).https://doi.org/10.1016/j.xcrm.2026.102758
- See more
Loading...
